Healthcare Ireland (NQS) Limited Small abridged accounts

HEALTHCARE IRELAND (NQS) LIMITED - Company Information

false false false false false false false false false true false false false false false false false No description of principal activity 2017-01-01 Sage Accounts Production Advanced 2017 Update 4 - FRS xbrli:pure xbrli:shares iso4217:GBP NI601419 2017-01-01 2017-12-31 NI601419 2017-12-31 NI601419 2016-12-31 NI601419 2016-12-31 NI601419 bus:Director1 2017-01-01 2017-12-31 NI601419 core:WithinOneYear 2017-12-31 NI601419 core:WithinOneYear 2016-12-31 NI601419 core:AfterOneYear 2017-12-31 NI601419 core:AfterOneYear 2016-12-31 NI601419 core:ShareCapital 2017-12-31 NI601419 core:ShareCapital 2016-12-31 NI601419 core:RetainedEarningsAccumulatedLosses 2017-12-31 NI601419 core:RetainedEarningsAccumulatedLosses 2016-12-31 NI601419 core:CostValuation core:Non-currentFinancialInstruments 2017-12-31 NI601419 core:Non-currentFinancialInstruments 2017-12-31 NI601419 core:Non-currentFinancialInstruments 2016-12-31 NI601419 bus:Director1 2016-12-31 NI601419 bus:Director1 2015-12-31 NI601419 bus:FRS102 2017-01-01 2017-12-31 NI601419 bus:AuditExempt-NoAccountantsReport 2017-01-01 2017-12-31 NI601419 bus:AbridgedAccounts 2017-01-01 2017-12-31 NI601419 bus:SmallCompaniesRegimeForAccounts 2017-01-01 2017-12-31 NI601419 bus:PrivateLimitedCompanyLtd 2017-01-01 2017-12-31

Statement of Consent to Prepare Abridged Financial Statements

All of the members of Healthcare Ireland (NQS) Limited have consented to the preparation of the abridged statement of income and retained earnings and the abridged statement of financial position for the year ending 31 December 2017 in accordance with Section 444(2A) of the Companies Act 2006.

COMPANY REGISTRATION NUMBER: NI601419

Healthcare Ireland (NQS) Limited

Filleted Unaudited Abridged Financial Statements

31 December 2017

Healthcare Ireland (NQS) Limited

Abridged Financial Statements

Year ended 31 December 2017

Contents	Page

Abridged statement of financial position	1

Notes to the abridged financial statements	3

Healthcare Ireland (NQS) Limited

Abridged Statement of Financial Position

31 December 2017

	2017		2016
Note	£	£	£

Fixed assets

Tangible assets	4	54,936	46,702
Investments	5	1,780	1,780
		--------	--------
		56,716	48,482

Current assets

Debtors	772,429	754,336
Cash at bank and in hand	29,011	63,830
	---------	---------
	801,440	818,166

Creditors: amounts falling due within one year	268,777		277,557
	---------		---------
Net current assets		532,663	540,609
		---------	---------
Total assets less current liabilities		589,379	589,091

Creditors: amounts falling due after more than one year	250,000	250,000
	---------	---------
Net assets	339,379	339,091
	---------	---------

Capital and reserves

Called up share capital	1	1
Profit and loss account	339,378	339,090
	---------	---------
Shareholders funds	339,379	339,091
	---------	---------

These abridged financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the abridged statement of income and retained earnings has not been delivered.

For the year ending 31 December 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476 ;

- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements .

Healthcare Ireland (NQS) Limited

Abridged Statement of Financial Position (continued)

31 December 2017

These abridged financial statements were approved by the board of directors and authorised for issue on 27 September 2018 , and are signed on behalf of the board by:

Mr G Yates
Director

Company registration number: NI601419

Healthcare Ireland (NQS) Limited

Notes to the Abridged Financial Statements

Year ended 31 December 2017

1. General information

The company is a private company limited by shares, registered in Northern Ireland. The address of the registered office is 631 Lisburn Road, Belfast, BT9 7GT.

2. Statement of compliance

These abridged financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The abridged financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The abridged financial statements are prepared in sterling, which is the functional currency of the entity.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

Investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.

Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Investments in associates

Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.

Investments in joint ventures

Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

4. Tangible assets

	£
Cost
At 1 January 2017	46,702
Additions	8,234
	--------
At 31 December 2017	54,936
	--------
Depreciation
At 1 January 2017 and 31 December 2017	–
	--------
Carrying amount
At 31 December 2017	54,936
	--------
At 31 December 2016	46,702
	--------

5. Investments

	£
Cost
At 1 January 2017 and 31 December 2017	1,780
	-------
Impairment
At 1 January 2017 and 31 December 2017	–
	-------
Carrying amount
At 31 December 2017	1,780
	-------
At 31 December 2016	1,780
	-------

6. Director's advances, credits and guarantees

During the year the director entered into the following advances and credits with the company:

	Balance brought forward and outstanding
	2017	2016
	£	£
Mr G Yates	16,121	( 1)
	--------	----

7. Related party transactions

The company was under the control of Mr G Yates throughout the year. Mr Yates is the managing director and only shareholder.